BioSpace News Archive

The implant disappears after fixation is completed, without leaving any foreign material on the tissue surface. Polyglycolic acid, polylactic acid, and polydioxanone are the predominantly used materials in the manufacture of bioabsorbable implants, as these have the ability to dissolve in the biological system.

Philogen S.p.A., a clinical-stage biotechnology company focused on antibody- and small molecule-based targeted therapeutics announces its Interim Results for the six month period ended 30th June 2021 and provides an update regarding recent corporate developments.

Avivagen Inc., a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that safely enhances feed intake and supports immune function, thereby supporting general health and performance, has announced its unaudited financial results for the third quarter of 2021.

Pfizer Inc. announced positive top-line results from a Phase 3 study evaluating the safety and immunogenicity of PREVNAR 20™ in adults 65 years of age or older when administered at the same time as the seasonal influenza vaccine.

GlucoModicum, a company transforming glucose monitoring with precise, needle-free magnetohydrodynamic (MHD) technology, announced today that it has signed a design and development collaboration with Phillips-Medisize, a Molex company, a global leader in front-end design, development and manufacturing for highly regulated industries such as pharma, diagnostics, and medtech.

Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today reported additional positive pulmonary function data from the first six patients in the ongoing IGNITE DMD Phase I/II clinical trial of SGT-001.

Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), and a company it founded, Caelum Biosciences, Inc. (“Caelum”), today announced that AstraZeneca’s Alexion notified Caelum that it has exercised its option to acquire Caelum.

Pharmazz, Inc. is pleased to announce that its Phase III clinical study of the drug candidate, centhaquine, has been approved by the US FDA for the treatment of hypovolemic shock.

Taysha Gene Therapies, Inc. today announced that it has been granted orphan drug designation from the European Commission for TSHA-101, an AAV9-based bicistronic gene replacement therapy in development for GM2 gangliosidosis, also called Tay-Sachs or Sandhoff disease.

Overland ADCT BioPharma Announces First Patient Dosed in China with ZYNLONTA ® in Pivotal Phase 2 Clinical Trial for Diffuse Large B-cell Lymphoma